HSI1 22,410.80 -430.82 270.30B
HSCEI1 7,554.37 -135.97 89.05B
Back    Zoom +    Zoom - Block Traded
UBS Keeps Buy on CSPC PHARMA with TP at HKD11.8 as 3Q Results Largely In Line
2026-11-20 13:23:07
UBS issued a research report stating that CSPC PHARMA (01093.HK)'s 3Q results were broadly in line with market expectations. The broker maintained its Buy rating and TP at HKD11.8.

The company's 3Q revenue was RMB6.7 billion, up 0.7% YoY and down 45% QoQ, above the broker's forecast of RMB6.2 billion and broadly in line with market expectations of RMB6.7 billion. Net profit attributable to shareholders was RMB982 million, up 1.9% YoY and down 81.2% QoQ, beating the broker's forecast of RMB239 million and market expectations of RMB864 million.

Earnings beat market expectations mainly due to other income, while operating profit was between the broker's and market forecasts. Gross margin and operating margin expanded by 1 ppt and 1.3 ppts YoY to 66.6% and 14.5%, respectively.
~

AASTOCKS Financial News
Website: www.aastocks.com